NETHERLANDS - ABN AMRO Capital Life Sciences invests in Amsterdam Molecular Therapeutics
ABN AMRO Capital Life Sciences (AAC LS) has announced that it has led a EUR 22m series-A financing of Amsterdam Molecular Therapeutics BV (AMT). The syndicate was completed by Advent Venture Partners, Gilde Investment Management and Crédit Agricole Private Equity. Sander Slootweg from ABN AMRO Capital Life Sciences has joined the company’s supervisory board.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater